Insider Purchases: Inside the Buy
Tag: Funanc1al Insider Series
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Healthpeak Properties (DOC): Insiders Are Buying—Should You?
📈 Healthpeak Properties (DOC) insiders are buying—and not just a little. But with a forward P/E north of 70 and a few post-merger integration challenges, is this stock still a hidden gem or more of a polished maybe? Dive in for the full take.
Not Everybody Likes Hunting, But Insiders Preyed On Sportsman's Warehouse's Stock
Sportsman's Warehouse (SPWH) may be wounded, but insiders are on the prowl. With CEO and directors buying stock, and a valuation that screams “cheap,” is this outdoor retailer staging a comeback? Time to load up—or duck?
Oxford Industries’s Tommy Bahama and Lilly Pulitzer Rock: Should You Emulate Insiders and Buy More Than the Brands?
Oxford Industries owns some of the most recognizable lifestyle brands—Tommy Bahama, Lilly Pulitzer, and Johnny Was. Sales are soft, but margins hold, insiders are buying, and the dividend is sweet. Time to sip a piña colada—and check the stock price?
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?
Oscar Health: Its Own Is Shining and Insiders Knew!
Co-founder Joshua Kushner and Thrive Partners bought over $23 million of Oscar Health stock in late 2024. Since then? Record earnings, soaring revenue, and a stock still (surprisingly) within range. A healthy bet — or just a well-insured hunch?
CEO Bought Shares: Is Full House Worth Betting the House?
Full House Resorts is growing fast—but still bleeding cash. The CEO’s massive insider buy may hint at a turnaround, but with debt looming and expansion plans on the table, is FLL worth a gamble? We break it down—odds, icons, and all.
Can Robinhood Still Steal the Show?
Robinhood’s got a new backer — and it’s no amateur. Christopher Payne (ex-DoorDash, Tinder, eBay) just went all in with a bold $2M+ insider buy. Add in huge crypto growth, a string of acquisitions, and global ambitions… and suddenly Robinhood doesn’t just look ready — it looks legendary. Is $HOOD still a buy? Let’s break it down.
Vera Bradley: The Bags Are Pretty; the Financials? Not So Much
The bags? Still adorable. The stock? Still near record lows. With insiders finally buying and a CEO exit underway, is Vera Bradley set for a stylish rebound — or is it still stuck in the clearance bin?
Quanterix Insiders Are Buying. Should You?
Quanterix insiders are buying, and institutions are still in. But revenue is sliding, and losses are deep. A potential comeback or another biotech burn? 🔬💸